Appco Pharma – Recall of ranitidine
January 7, 2020 - Appco Pharma announced a voluntary, consumer-level recall of prescription ranitidine capsules because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA.
Download PDF
